Hyperthyroidism

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  

Retrieved on: 
Mittwoch, April 10, 2024
Consensus, Glaucoma, Conditional sentence, University, Finance, RMB, Risk, Approximation error, Patient, Artificial intelligence, Medical device, National Health Commission, Optometry, Endocrinology, Dementia, Certification, Hyperthyroidism, Ageing, Capital Medical University, Software, MICCAI, Hypertensive retinopathy, Beijing Tongren Hospital, Neurology, Acceleration, Intelligence, Paratriathlon, Hospital, Research, Near-sightedness, Amblyopia, AI, MDR, Strabismus, Skin, AMD, Ranibizumab, Diagnosis, Peking University, Growth, Cardiology, Physical examination, News, Cataract, Diabetic retinopathy, Ophthalmology

In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points: 
  • In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.
  • 2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
  • Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
  • In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Retrieved on: 
Mittwoch, April 10, 2024
Tsinghua University, OCTA, Alzheimer's disease, Finance, CE, Patient, Artificial intelligence, Adolescence, World's fair, Medical device regulation, Dementia, CNV, Certification, Hyperthyroidism, HK, Partnership, Policy, MICCAI, Safety, Lighting, Optical coherence tomography angiography, Intelligence, Choroidal neovascularization, Journal, Hospital, Research, Near-sightedness, Amblyopia, AI, Insurance, Strabismus, AMD, Gold medal, Diagnosis, Peking University, Conference, Growth, Biomarker, Plaque, News, Bleeding, Google Images, Rehabilitation, Medical device

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Key Points: 
  • Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases
    On March 27, medical artificial intelligence company Airdoc Technology (2251.
  • In 2023, through our SaMDs and health risk assessment solutions, we serviced a total of 6.83 million cases and identified 31,459 significant positive cases.
  • In 2023, Airdoc Medical broadened its reach to include hospitals, grassroots medical institutions such as community clinics, and health examination centers.
  • In June 2023, Airdoc, in collaboration with Tsinghua University's Chang Gung Hospital, developed and validated a new deep learning-based neovascular segmentation model.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Montag, März 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Retrieved on: 
Montag, Februar 12, 2024
TED, Neonatal Fc receptor, Injection, Research, CIDP, LDL, Common stock, Calendar, Serum albumin, IPR, Immunoglobulin G, Information technology, Hyperthyroidism, Patient, Clinical trial, Neurology, Cryptocurrency

NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.

Key Points: 
  • NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.
  • “We have laid a strong and exciting foundation for Immunovant,” said Pete Salzmann, M.D., chief executive officer at Immunovant.
  • Financial Highlights for Fiscal Third Quarter Ended December 31, 2023:
    Cash Position: As of December 31, 2023, Immunovant’s cash and cash equivalents totaled approximately $691 million.
  • IPR&D Expenses: There were no acquired in-process research and development expenses for the three months ended December 31, 2023.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Freitag, Januar 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

Retrieved on: 
Mittwoch, Dezember 20, 2023
Patient, Hyperthyroidism, ATD, Injection, Safety, Immunoglobulin G, Pharmaceutical industry

This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves’ disease.

Key Points: 
  • This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves’ disease.
  • Treatment response is defined as normalization of T3 and T4 hormone levels without increasing ATD dose.
  • A similar dose response was observed for anti-TSHR autoantibodies, with deeper reductions observed following treatment with 680 mg of SC batoclimab as compared to 340 mg of SC batoclimab.
  • Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

Retrieved on: 
Mittwoch, Dezember 20, 2023
Patient, Hyperthyroidism, ATD, Injection, Safety, Immunoglobulin G, Pharmaceutical industry

This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves’ disease.

Key Points: 
  • This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves’ disease.
  • Treatment response is defined as normalization of T3 and T4 hormone levels without increasing ATD dose.
  • A similar dose response was observed for anti-TSHR autoantibodies, with deeper reductions observed following treatment with 680 mg of SC batoclimab as compared to 340 mg of SC batoclimab.
  • Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.

Food And Drug Administration Grants Two New Label Changes To Tirosint®-Sol (Levothyroxine Sodium) Oral Solution

Retrieved on: 
Montag, Dezember 4, 2023
Biotechnology, FDA, Managed Care, Health, General Health, Women, Seniors, Pharmaceutical, Research, Consumer, Science, Breakfast, Heat intolerance, Absorption, Food, Hypothyroidism, Eating, Commercial Operating System, Irritability, Headache, Risk, Tremor, Arrhythmia, IBSA, Rash, Cardiovascular disease, Insurance, Patient, Diabetes, Myocardial infarction, Periodic breathing, Appetite, Atrial fibrillation, Muscle weakness, Enzyme inhibitor, Adrenal insufficiency, Diarrhea, Menstruation, University, Water, Insomnia, PPI, Glycerol, Common, Spasm, Nervous, Hyperthyroidism, Weight loss, Pharmacy, Pharmaceutical industry, Dietary supplement, Levothyroxine

The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.
  • The first regards the use of Tirosint-SOL in the presence of proton pump inhibitor (PPI) therapy.
  • Both label changes help to differentiate Tirosint-SOL from other levothyroxine therapies.
  • Similarly, current labeling for all levothyroxine sodium therapies instructs patients to self-administer the drug once daily, on an empty stomach, one-half to one hour before breakfast.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Montag, September 11, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Montag, September 11, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.